Dataset from A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009299
下载链接
链接失效反馈官方服务：
资源简介：
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with
previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either
lumiliximab in combination with FCR or FCR alone.
创建时间：
2024-11-26
